Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M608482200 on December 13, 2006

J. Biol. Chem., Vol. 282, Issue 9, 5991-6000, March 2, 2007
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/9/5991    most recent
M608482200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, H.
Right arrow Articles by Mourad, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, H.
Right arrow Articles by Mourad, W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Zinc Induces Dimerization of the Class II Major Histocompatibility Complex Molecule That Leads to Cooperative Binding to a Superantigen*

Hongmin Li{ddagger}§1, Yiwei Zhao{ddagger}2, Yi Guo{ddagger}, Zhong Li{ddagger}, Leslie Eisele{ddagger}, and Walid Mourad

From the {ddagger}Wadsworth Center, New York State Department of Health, the §Department of Biomedical Sciences, School of Public Health, University at Albany, State University of New York, Albany, New York 12208, and Université de Montréal, Centre Hospitalier de l'Université de Montréal, Campus St-Luc, Pavillon Edouard Asselin, 264, Boulevard RenéLévesque Est, Bureau 313, Montréal, Québec H2X 1P1, Canada

Received for publication, September 5, 2006 , and in revised form, December 5, 2006.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Dimerization of class II major histocompatibility complex (MHC) plays an important role in the MHC biological function. Mycoplasma arthritidis-derived mitogen (MAM) is a superantigen that can activate large fractions of T cells bearing specific T cell receptor Vbeta elements. Here we have used structural, sedimentation, and surface plasmon resonance detection approaches to investigate the molecular interactions between MAM and the class II MHC molecule HLA-DR1 in the context of a hemagglutinin peptide-(306–318) (HA). Our results revealed that zinc ion can efficiently induce the dimerization of the HLA-DR1/HA complex. Because the crystal structure of the MAM/HLA-DR1/hemagglutinin complex in the presence of EDTA is nearly identical to the structure of the complex crystallized in the presence of zinc ion, Zn2+ is evidently not directly involved in the binding between MAM and HLA-DR1. Sedimentation and surface plasmon resonance studies further revealed that MAM binds the HLA-DR1/HA complex with high affinity in a 1:1 stoichiometry, in the absence of Zn2+. However, in the presence of Zn2+, a dimerized MAM/HLA-DR1/HA complex can arise through the Zn2+-induced DR1 dimer. In the presence of Zn2+, cooperative binding of MAM to the DR1 dimer was also observed.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Major histocompatibility complex (MHC)3 molecules can present a wide variety of antigens to T lymphocytes. Two classes, class I and class II MHC, recognized by CD8+ and CD4+ T lymphocytes, respectively, have been discovered. Class II MHC molecules are heterodimers, composed of an {alpha}-chain and a beta-chain. These {alpha}beta heterodimers are highly polymorphic, type I integral membrane proteins, assembled in antigen-presenting cells (APCs) such as B cells and macrophages. Because the first crystal structure of a class II MHC molecule was reported in 1993 (1), crystal structures of more than 20 MHC class II molecules from both human and mouse have been determined. Some of these structures have revealed that the MHC class II heterodimer can self-associate to further form a({alpha}beta)2 double dimer, termed the superdimer (2). In the crystals the superdimer is arranged in such a way that allows simultaneous binding of two T cell receptors (TCRs) and two CD4 molecules (2). Dimerization of class II MHC, either as preformed complexes on the APC membrane or as induced upon TCR engagement, appears consistent with many aspects of class II immunology, including signaling and T cell activation (2–4). However, it remains controversial as to whether the crystallographic superdimer constitutes evidence that the superdimer exists as a physiologically relevant conformation of MHC class II (5–8).

In addition to peptide antigens, class II MHC can present a number of proteins, known as superantigens (SAgs), to T lymphocytes (9, 10). Upon binding to the MHC class II molecules on APCs, SAgs are recognized by TCRs carrying specific Vbeta subsets, leading to polyclonal activation of a large portion (up to 20%) of T lymphocytes. SAgs have been hypothesized to play important roles in a number of human diseases, including food poisoning, toxic shock syndrome, and autoimmune diseases such as multiple sclerosis and rheumatoid arthritis (10–14).

SAgs are known to bind to the MHC molecules in diverse ways. Currently, two sites have been identified on the MHC, one with a low binding affinity for SAgs and the other with a high affinity (9, 15, 16). The low affinity site (KD = 10–5 M) is on the MHC {alpha}1 domain, whereas the high affinity site (KD = 10–7 M), which is Zn2+-coordinated, is on the MHC beta-chain. Some SAgs have a single MHC-II-binding site; for instance, staphylococcal enterotoxin B and toxic shock syndrome toxin-1 bind only to the MHC {alpha}-chain (17, 18). Others, such as SEA, bind to both low and high affinity sites on MHC-II (15, 19). In addition, it has been proposed that dimerization or oligomerization of the MHC antigens by SAgs is critical for T cell activation (20–24).

MAM is a potent T cell mitogen produced by Mycoplasma arthritidis (25), a natural pathogen of rodents. MAM can induce spontaneous chronic arthritis, which resembles human rheumatoid arthritis, in genetically susceptible strains of rodents. In vitro, administration of MAM can induce MHC class II-dependent T cell activation in a Vbeta-restricted fashion, leading to B cell proliferation and differentiation and triggering cytokine expression (26). A structural study revealed that a MAM dimer can cross-link to two MHC molecules via interactions with the MHC {alpha}1 domains (27). It was also reported that the superantigenic activity of MAM via MHC class II molecules is Zn2+-dependent (28–30).

In this study, we have used structural, sedimentation, and surface plasmon resonance (SPR) detection approaches to investigate the molecular interactions between MAM and class II MHC molecule HLA-DR1, in the context of a hemagglutinin peptide (HA). Unexpectedly, we find that Zn2+ can induce the dimerization of a soluble class II MHC HLA-DR1/HA complex in solution. We also find that MAM binds the HLA-DR1/HA complex at a 1:1 stoichiometry, with a high affinity, and independent of zinc ion. Although Zn2+ is not directly involved in the binding between MAM and HLA-DR1, Zn2+-induced dimerization of the HLA-DR1/HA complex resulted in a dimerized MAM·MHC complex, in which cooperative binding of MAM to the HLA-DR1/HA complex dimer was observed.


   EXPERIMENTAL PROCEDURES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
RESULTS
 DISCUSSION
 REFERENCES
 
Protein Production—Soluble MAM was expressed as a glutathione S-transferase fusion protein as described previously (27, 31, 32). The HLA-DR1/HA complex was prepared using a refolding protocol as described (27, 32, 33).

To generate biotinylated HLA-DR1 with covalently linked HA peptide for the BIAcore binding study, we made a new construct, using a two-step PCR protocol. Two sets of overlapping primers (forward, 5'-GGAATTCCATATGCCCAAGTATGTTAAGCAAAACACCCTGAAGTTGGCAACAGGAGGTGGTGGCTCACTA-3' and 5'-GGAGGTGGTGGCTCACTAGTGGGAGGGGGCTCTGGAGGAGGTGGGTCCGGG-3'; reverse, 5'-GTCGTTCAGACCACCGCCGCTAGCTCCACCCCTAGTGGACTGTGCTCTCCATTCCACTGTGAG-3' and 5'-CCCAAGCTTTCATTCGTGCCATTCGATTTTCTGAGCCTCGAAGATGTCGTTCAGACCACCGCCGCT-3') were designed to amplify the DR1beta, the linkers, the HA peptide-(306–318), and a BirA recognition peptide (34). The amplified DNA was then ligated to the pET26b vector (Novagen) using the NdeI and HindIII sites (underlined in the primer sequences). The HA peptide was covalently linked to the N terminus of DR1beta through a flexible linker (GGGGSLVGGGSGGGGS) similar to that used in our previous study (29). The engineered DR1beta also contained a C-terminal amino acid tag encoding a linker (QSTRGGASGG) and a signal sequence (GLNDIFEAQKIEWHE) for attaching biotin with the BirA enzyme (34, 35). Modified HA-DR1beta was expressed, solubilized, and refolded with DR1{alpha}, using a protocol as described (27, 32, 33), with a modification that no synthetic HA peptide was added. Correctly folded HA/HLA-DR1 complex was purified, using ion exchange chromatography, on a Mono Q column (GE HealthCare); it was biotinylated with the BirA enzyme (Avidity), and size-purified on a Superdex 200 FPLC column (GE HealthCare). The extent of biotinylation was estimated with the EZ biotin quantitation kit (Pierce). Typically, 99% of the protein was biotinylated.

Crystallization—Crystals of the MAM/HLA-DR1/HA complex were grown under the conditions described previously (27, 32), except that EDTA was substitute for Zn(OAc)2. Crystals of the complex were also grown in the absence of both EDTA and Zn2+. To fully address whether zinc is involved in the complex formation, we soaked the complex crystals from the no-EDTA and no-Zn2+condition in the mother liquor containing 10 mM CdCl2. If a protein is known to bind zinc, cadmium ion is frequently used to substitute zinc for the determination of protein structure using the multiple isomorphous replacement method (36, 37). Microseeding was used to produce large crystals for x-ray diffraction data collection.

X-ray Diffraction Data Collection, Structure Determination, and Refinement—Crystals of the complex obtained in the absence of zinc ion or in the presence of EDTA are isomorphous with the crystals previously obtained in the presence of zinc ion (27, 32). Diffraction data for crystals of the MAM·DR1 (no-Zn2+), MAM·DR1 (EDTA), and MAM·DR1 (Cd2+) complexes were collected at 100 K at beamline X25 of the National Synchrotron Light Source at the Brookhaven National Laboratory (Table 1).


View this table:
[in this window]
[in a new window]

  		TABLE 1
Data collection, refinement, and model details

 
The crystal structure of the MAM/HLA-DR1/HA complex at 2.6 Å resolution (27) was served as a starting model for structural refinement, using CNS (38) with a protocol similar to that described previously (27). Noncrystallographic symmetry restraints defined by pairs of individual domain were used throughout the refinement. The refinement statistics are summarized in Table 1.

Analytical Ultracentrifugation (AUC) Sedimentation Velocity—Sedimentation velocity (SV) experiments were conducted at 20 °C in a Beckman Optima XL-I analytical ultracentrifuge at a rotor speed of 50,000 rpm. Double-sector cells were loaded with 400 µl of proteins samples and with 410 µl of reference solutions, respectively. Unless otherwise specified, the reference solution is Hepes-buffered saline (HBS) containing 10 mM Hepes buffer (pH 7.4), 150 mM NaCl. In certain experiments, 2 mM EDTA or ZnCl2 was added to both protein and reference solutions. Data were recorded with absorbance detection at wavelengths of 280, 294, and 300 nm for low, moderate, and high concentrations of proteins, respectively. Absorbance profiles were analyzed with the software SEDFIT (39), using a model for continuous sedimentation coefficient distributions c(s) (40). Distributions were calculated with maximum entropy regularization at a predetermined confidence level of 1 S.D.

AUC Sedimentation Equilibrium—Sedimentation equilibrium studies were conducted at a temperature of 20 °C and at three or four rotor speeds for each protein or mixture. The individual protein or protein mixture (100 µl) at various concentrations in HBS, with or without EDTA/ZnCl2, was loaded into an Epon double-sector centerpiece. Reference cells were loaded with 110 µl of reference solution. For the MAM/HLA-DR1/HA complex in the presence of 5 mM EDTA, mixtures of MAM and DR1 at various molar ratios and concentrations (5:2, 5:3, 15:1, and 1:4, in a real micromolar ratio of concentrations for MAM:HLA-DR1) were used for sedimentation equilibrium analysis with three rotor speeds (20,000, 25,000, and 30,000 rpm). For the complex with 1 mM ZnCl2, MAM and DR1, at 16:1 and 8:0.5 in a real micromolar ratio of concentrations, were analyzed with four rotor speeds (15,000, 20,000, 25,000, and 30,000 rpm). For DR1 alone, sedimentation equilibrium of DR1 was analyzed at concentrations of 1 and 5 µM with or without 1 mM ZnCl2, with three rotor speeds (18,000, 21,000, and 24,000 rpm). In the Zn2+ titration experiment for DR1 alone, 2 µM DR1 was used with various Zn2+ concentrations (0, 0.001, 0.01, 0.1, 0.3, 0.5, 0.7, and 1 mM). For MAM alone, the equilibrium experiment was conducted at protein concentrations of 2 and 15 µM, with or without 1 mM ZnCl2, and with three rotor speeds (20,000, 25,000, and 30,000 rpm).

All equilibrium absorbance profiles were acquired at a 280-nm wavelength. The equilibrium sedimentation data were analyzed using the software SEDPHAT (39). Data analysis was performed by global least squares analysis of data from multiple concentrations and multiple rotor speeds, using conservation of mass constraints (39).

Affinity Measurement Using SPR—Affinity and kinetic analyses of the interactions between MAM and HLA-DR1/HA were determined using a BIAcore 3000 SPR instrument (BIAcore) at 25 °C. Biotinylated HLA-DR1/HA complex was immobilized (~260 RU) onto a streptavidin (SA) sensor chip (BIAcore). The concentrations used for the injected MAM samples ranged from 8 µM to 32 nM, with 2-fold dilutions. A blank surface blocked by biotin was used as the control surface. To minimize nonspecific binding, we carried out all of the binding experiments in 10 mM Hepes buffer containing 1 M sodium chloride, 3.4 mM EDTA, 0.005% surfactant P20, at a flow rate of 30 µl/min. Pulses of 10 mM NaOH were used to regenerate both surfaces between injections. Association (kon) and dissociation (koff) rates, as well as the dissociation constant (KD), were obtained by global fitting of the SPR data from multiple concentrations to a simple 1:1 Langmuir binding model, using BIAevaluation software version 4.1.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
DISCUSSION
 REFERENCES
 
Crystal Structures of the MAM/HLA-DR1/HA Complex in the Presence of EDTA—Previously, we determined the crystal structure of a MAM/HLA-DR1/HA complex (27). No Zn2+ could be detected coordinated into the crystals, even though the crystallization buffer contained 1 mM Zn(OAc)2 (27, 32). However, zinc has been reported to be critical for the biological function of MAM (29–31). To better understand the role of zinc in the biological activity of MAM, we determined the crystal structures of the binary complex under several contrasting conditions. The MAM/HLA-DR1/HA complex was successfully crystallized under conditions, similar to those previously described (32), but in the absence of Zn(OAc)2 and/or in the presence of 2 mM EDTA (see "Experimental Procedures"). These new crystals are isomorphous with those obtained under the Zn2+ condition. We also soaked the complex crystals in the mother liquor with 10 mM CdCl2.

Diffraction data were collected to 2.8, 3.0, and 2.6 Å resolution for the crystals without Zn2+, with EDTA, and with Cd2+, respectively. The crystal structures of these complex crystals were refined to Rfactor values of 27.2% (no Zn2+), 21.1% (EDTA), and 23.4% (Cd2+), with Rfree values of 31.2, 26.1, and 26.6%, respectively (Table 1). The structures determined from these crystals can be readily superposed with the structure of the complex crystal obtained in the presence of Zn2+ (Fig. 1) (27). The root-mean-square (r.m.s.) deviations in the C-{alpha} positions of all amino acids among these structures are within 0.35 Å. For the Cd2+-soaked crystals, no Cd2+ ion could be located in the electron density map. These structures could suggest that the Zn2+ ion is not directly involved in the interaction between MAM and class II MHC molecules.

MAM Binds to the HLA-DR1/HA Complex with a 1:1 Stoichiometry, in the Absence of Zn2+—To further investigate the molecular interaction between MAM and class II MHC molecule, we performed sedimentation velocity analytical ultracentrifugation with individual proteins and mixtures (Fig. 2).

Previously, we demonstrated that MAM exists as a monomer at low protein concentration (≤11 µM) and that it can dimerize at high concentrations (≥25 µM) independent of Zn2+ (41). The MAM monomer showed a single peak with a sedimentation coefficient (S) of about 2.1 (Fig. 2A), whereas the S value for a MAM dimer is 3.0 (41). In the absence of Zn2+ ion, the HLA-DR1/HA complex showed a large peak, corresponding to a DR1 monomer, at 3.3 S (Fig. 2A). The sedimentation coefficient distribution of a mixture of 6 µM MAM and 6 µM HLA-DR1/HA showed two peaks at 2.1 and 4.0 S, respectively. The peak at 2.1 S corresponds to residue-unbound MAM monomer, whereas the peak at 4.0 S represents some species other than the unbound HLA-DR1/HA complex (at 3.3 S). This result demonstrates an interaction between the two molecules. Indeed, the value of the new peak at 4.0 S is very close to the S value (4.1 S) predicted by hydrodynamic modeling of a MAM/HLA-DR1/HA complex with a 1:1 stoichiometry. Increasing the protein concentrations of MAM (to 30 µM) and HLA-DR1/HA (to 10 µM) resulted in a peak for the sedimentation coefficient at 4.0 S, similar to that for the MAM·DR1 complex at low protein concentrations (Fig. 2). Addition of EDTA to the MAM/HLA-DR1/HA complex did not alter the 4.0 S peak position (Fig. 2B). These experiments demonstrated that MAM forms a complex with the HLA-DR1/HA complex in a 1:1 stoichiometry. Because addition of EDTA to the MAM/HLA-DR1/HA complex mixture did not change the sedimentation profile, we conclude that formation of the MAM/HLA-DR1/HA complex is not dependent on divalent metal ions such as Zn2+.


Figure 1
View larger version (55K):
[in this window]
[in a new window]

  		FIGURE 1.
Structural comparison of the MAM/HLA-DR1/HA complex crystallized under different conditions as follows: 1 mM Zn(OAc)2 (black); no Zn2+, EDTA, or Cd2+ (light gray).

 


Figure 2
View larger version (23K):
[in this window]
[in a new window]

  		FIGURE 2.
Sedimentation-velocity analysis of the binding of MAM to HLA-DR1/HA. A, sedimentation coefficient distributions of MAM alone ({Delta}), of DR1 alone ({circ}), and of mixtures at different ratio of concentrations as follows: MAM:DR1 = 6:6 µM ({square}); = 30:10 µM ({blacksquare}); and = 5:10 µM (•) in the absence of Zn2+. B, sedimentation coefficient distributions of DR1 alone and MAM/DR1 mixtures under various conditions. {square}, 8 µM DR1 with 1 mM EDTA; {square}, 15 µM DR1 with 1 mM ZnCl2; {circ}, 6 µM MAM and 4 µM DR1 with 1 mM EDTA; {Delta}, 6 µM MAM and 4 µM DR1 with 1 mM ZnCl2; •, 16 µM MAM and 1 µM DR1 with 1 mM ZnCl2; {diamondsuit}, 16 µM MAM and 1 µM DR1 with 1 mM ZnCl2 and 10 mM EDTA.

 
MAM Binds to the HLA-DR1/HA Complex with High Affinity, in the Absence of Zn2+—By the SPR technique, we measured the affinity and kinetics of MAM binding to the HLA-DR1/HA complex. We produced a C-terminal biotinylated DR1 molecule using a strategy similar to that described by Wu et al. (42) (Fig. 3A). A construct was made to express the beta-chain of HLA-DR1 with an HA peptide covalently linked to its N terminus through a linker peptide similar to what we and others described previously (29, 43). In addition, an amino acid tag encoding a signal sequence for attaching biotin with the BirA enzyme was attached to the C terminus of the DR1 beta-chain through a peptide linker as described (42).

The biotinylated HLA-DR1/HA complex was immobilized onto an SA sensor chip, for binding and kinetic studies with MAM. To obtain accurate kinetic data and minimize potential mass transport effects, we optimized experimental conditions by immobilizing biotinylated-DR1 at a low ligand density (260 RU), and by introducing a high concentration of NaCl in the running buffer (see "Experimental Procedures"). As shown in Fig. 3B, a concentration-dependent binding to the immobilized HLA-DR1/HA complex was observed for MAM. The data were successfully fitted by a 1:1 model, with a low deviation ({chi}2) of 0.3. The fast association rate (kon) and slow dissociation rate (koff) were determined to be 2.18 x 104 M–1 s–1, and 1.35 x 10–2 s–1, respectively. Thus, a binding affinity (dissociation constant, KD) of 0.6 µM was obtained for the interaction of MAM with HLA-DR1/HA.

The affinity KD of 0.6 µM is lower than the value (25 nM) that we previously measured using a 125I-labeled cellular competition assay (29). The discrepancy could result from several factors. One obvious factor that may attribute to this discrepancy is the difference in method. In the SPR method, what we measure is the binding affinity between MAM and the HLA-DR1/HA complex; in the cell-based method, however, the class II MHC molecules are associated with additional co-receptors that could increase the overall binding affinity of MAM to the receptor complexes. In vivo, HLA-DR molecules expressed on human B cells are loaded with a mixture of peptides. We have demonstrated that a significant portion of the interface between MAM and the HLA-DR1/HA complex in the co-crystal structure is contributed by the HA peptide at the MHC peptide-binding groove (27). Therefore, differences in the MHC-loaded peptides could result in differences in the binding affinity of HLA-DR for MAM. Our previous functional studies also suggested that the MHC-loaded peptides influence the presentation of MAM to T cells (29). In the SPR analysis, there could be other factors that give rise to a weaker binding affinity. For instance, the high salt BIAcore running buffer could weaken the binding of MAM to the immobilized HLA-DR1 molecule. Analysis of the crystal structure of the MAM/HLA-DR1/HA complex indicated that as many as 19 hydrogen bonds, including several salt bridges, are present at the interface of the complex (27). Although mutagenesis studies have not been performed on the interacting residues, it is a reasonable assumption that electrostatic forces play an important role in the binding between the two molecules. Therefore, high salt concentration could decrease the extent of electrostatic-dependent binding and give rise to a weaker binding affinity. As the salt concentration was increased, various folds of decrease in binding affinities have been observed in an SAg-TCR-Vbeta system (44). In the SPR analysis, another factor that could contribute to a weaker binding affinity is ligand immobilization. Although we immobilized the HLA-DR1/HA complex under a very gentle condition via the DR1beta C-terminal biotin that is at the opposite end of the MAM-binding site of DR1, partial inactivation of the HLA-DR1/HA complex or steric hindrance to block the access of MAM to the binding site cannot be completely ruled out. It has been reported that immobilization can result in complete loss of binding activity (45, 46).


Figure 3
View larger version (20K):
[in this window]
[in a new window]

  		FIGURE 3.
Affinity measurement of binding of MAM to the HLA-DR1/HA complex in the absence of Zn2+. A, SDS-PAGE analysis of biotinylated HLA-DR1/HA complex. Lane 1, Bio-Rad broad range molecular weight standard; lane 2, biotinylated HLA-DR1/HA complex under boiled condition; lane 3, biotinylated HLA-DR1/HA complex under nonboiled condition. B, BIAcore sensograms of kinetic data for MAM binding to the HLA-DR1/HA complex with the high salt HBS-EP buffer (10 mM Hepes (pH 7.4), 1 M NaCl, 3.4 mM EDTA, 0.05% P-20). Biotinylated HLA-DR1/HA complex was coupled to an SA chip (~260 RU). The concentrations for the injected MAM samples were from 8 µM to 32 nM, with 2-fold dilutions. Global fitting of data to a 1:1 binding model is shown in dark black. C, sedimentation equilibrium analysis of MAM binding to the HLA-DR1/HA complex in the presence of 5 mM EDTA. Representative absorbance distributions for the sedimentation equilibrium of 5 µM MAM mixed with 3 µM HLA-DR1/HA at 20 °C at rotor speeds of 20,000 rpm ({square}), 25,000 rpm ({circ}), and 30,000 rpm ({triangleup}). Distributions were analyzed as part of a global fitting to the absorbance data at multiple loading concentrations. Solid lines are the global best fit distributions using a reversible A + B {leftrightharpoons} AB model.

 
To address the discrepancy in values obtained for the binding affinity between MAM and HLA-DR1, between our earlier study and the present one, we used an alternative technique, the AUC sedimentation equilibrium method, to provide another determination of the binding affinity. The sedimentation equilibrium is an efficient AUC method for measuring the KD values for reversible protein-protein interactions (39). Because both interacting species are in solution, any possible artifacts arising from chemical modifications such as ligand immobilization in the SPR analysis could be avoided. When 3 µM HLA-DR1/HA was mixed with 5 µM MAM molecule in the presence of 5 mM EDTA, we were able to model the sedimentation equilibrium data using a noninteracting single species model, with a reasonable r.m.s. deviation of A280, but a relatively large global {chi}2 of 2.3 (data not shown). By using SETPHAT (39), we obtained an apparent molecular mass of 62.8 kDa, with the molecular mass being the only fitting parameter. This value is significantly larger than the calculated molecular mass for MAM (25.7 kDa) and that for the HLA-DR1/HA complex (44.5 kDa), but it is smaller than the mass for a MAM/HLA-DR1/HA complex (70.2 kDa). This result is in good agreement with the fact that the apparent molecular mass estimated from analysis of sedimentation equilibrium data represents an average molecular mass for the equilibrium mixture, in which MAM (the smaller species) is in slight excess. Therefore, the resulting mass for such a mixture is expected to be smaller than the theoretically calculated mass for the complex. Nevertheless, although it was not a perfect fit, this result indicated an interaction between MAM and the HLA-DR1/HA complex. Indeed, when we analyzed the equilibrium data from multiple concentrations and multiple speeds with a (A + B {leftrightharpoons} AB) hetero-association model using SEDPHAT (40), a much better fitting was obtained. Fig. 3C showed a representative fitting of the experimental equilibrium data. A KD of 0.1 µM was obtained, with a much improved global {chi}2 of 1.4 and an r.m.s. deviation of 0.005 OD.

The affinity (0.1 µM) determined using sedimentation equilibrium is higher than that (0.6 µM) determined by BIAcore and is much closer to that (25 nM) determined using the cell-based assay that likely involved other factors for binding with MAM (29). It has been reported that the KD values obtained by sedimentation equilibrium are consistently higher than those from BIAcore (46). It was suggested that the sedimentation equilibrium values could more accurately reflect the true binding constants, given that the sedimentation method does not involve chemical coupling of ligands to a solid support (46). In our case, the KD value determined by sedimentation is more trustworthy, because we used near physiological condition (low salt concentration) in the sedimentation, in contrast to the high salt concentration used in the BIAcore analysis.

Nevertheless, the affinity determined by both methods could be regarded as high for the interactions between TCR, SAg, and MHC (9). Because the running buffers for our SPR and equilibrium analyses contained excessive amounts of EDTA, our result clearly indicated that Zn2+ is not directly involved in the high affinity binding of MAM with class II MHC, the HLA-DR1/HA complex.

Zn2+ Promotes Dimerization of the MAM/HLA-DR1/HA Complex—Although Zn2+ does not directly participate in the binding between MAM and class II MHC, it is possible that Zn2+ may be involved in modulation of the MAM·MHC complex through other mechanisms. For instance, Zn2+ has been found to be important in dimerization of the MAM/HLA-DR1/HA complex (30); such dimerization of the complex is critical for the biological function of SAg (29, 31).

To investigate the role of zinc in the MAM·MHC interaction, we repeated the SV experiment for the MAM/HLA-DR1/HA complex but in the presence of Zn2+. As shown in Fig. 2B, a mixture of 6 µM MAM and 4 µM HLA-DR1/HA led to a new S value (6.0 S) for the complex. The S value at 6.0 corresponds to an MAM/HLA-DR1/HA complex with a 2:1 stoichiometry of HLA-DR1 to MAM, implying that a partial dimerization of the MAM/HLA-DR1/HA complex was occurring. We also noticed that a small shoulder peak between 4.0 S and 5.0 S exists for the complex in the presence of zinc (Fig. 2B). This shoulder peak should represent the MAM/HLA-DR1/HA complex in a 1:1 stoichiometry. The co-existence of the MAM·DR1 and MAM·(DR1)2 complexes may indicate that the binding sites of two HLA-DR1/HA molecules were not fully saturated under our experimental conditions.

To obtain a completely dimerized complex, we increased the micromolar ratio to 16:1 for MAM (16 µM) and the HLA-DR1/HA complex (1 µM). In the presence of Zn2+, a new broad peak emerged at 6.6 S in the velocity sedimentation profile (Fig. 2B). Hydrodynamic modeling of a 2:2 MAM·MHC complex leads to a predicted S value of 6.5. Our data thus demonstrate that Zn2+ promotes the dimerization of the MAM/HLA-DR1/HA complex. Indeed, addition of 10 mM EDTA to MAM/HLA-DR1/HA complex suppressed the effect caused by addition of 1 mM Zn2+, resulting in a peak at 4.0 S that represents a MAM/HLA-DR1/HA complex in a 1:1 stoichiometry (Fig. 2B). These results indicated that dimerization of the MAM/HLA-DR1/HA complex is Zn2+-dependent.

Dimerization of the MAM/HLA-DR1/HA Complex Is Mediated by a Zn2+-dependent HLA-DR1/HA Dimer—The dimerization of the MAM·MHC complex could be mediated by a dimer of either MAM or the HLA-DR1 molecule. We have shown previously that MAM only dimerize at a high protein concentration and that MAM dimerization is independent of Zn2+ (41). This implies that the dimerized MAM·MHC complex is mediated by a Zn2+-dependent HLA-DR1/HA dimer. However, whether Zn2+ can induce dimerization of the HLA-DR1/HA complex requires experimental confirmation. Therefore, we performed an SV experiment for the HLA-DR1/HA complex with Zn2+ or both EDTA and Zn2+. Addition of 1 mM Zn2+ to the HLA-DR1 solution (15 µM) resulted in a sedimentation coefficient peak at 5.2 S (Fig. 2B), corresponding to a HLA-DR1 dimer. The addition of 10 mM EDTA to the Zn2+-incubated HLA-DR1 solution resulted in a monomer peak for the DR1 molecule at 3.3 S (Fig. 2B). To investigate the effective concentration for dimerization of the HLA-DR1/HA complex in the presence of Zn2+, we lowered the concentration of the MHC molecule. Our experiment demonstrated that the HLA-DR1/HA complex forms a dimer in the presence of 1 mM Zn2+ at a concentration as low as 0.28 µM (data not shown). Because of experimental limitations, we could not use a HLA-DR1 concentration lower than 0.28 µM. Nevertheless, our data demonstrate that Zn2+ triggers the dimer formation of the HLA-DR1/HA complex. This implies that the dimerized MAM/HLA-DR1/HA complex is formed via a Zn2+-mediated HLA-DR1 dimer.

Determination of the Dissociation Constant of the DR1 Dimer—To verify our SV results and to determine the dissociation constant of the DR1 dimer, we performed sedimentation equilibrium studies, either in the presence or in the absence of Zn2+, for the HLA-DR1/HA complex and for MAM by itself (Fig. 4).

At equivalent protein concentrations (15 µM), the sedimentation equilibrium profile for MAM with 1 mM Zn2+ was very similar to that for MAM without ZnCl2 (Fig. 4A). The subtle differences between the two equilibrium profiles could result from small differences in the effective concentration of MAM loading in two different cells. Indeed, with a single species model, modeling of the equilibrium data of MAM with or without Zn2+ resulted in similar molecular mass values, with excellent global {chi}2 and r.m.s. deviation (Fig. 4A). This supported our previous conclusion that Zn2+ is not involved in the dimerization of MAM. In contrast, at a protein concentration of 5 µM, it is obvious that the sedimentation profile for DR1 in HBS buffer supplemented with 1 mM ZnCl2 is very different from that for DR1 in HBS buffer only (Fig. 4B). By using SETPHAT (39), we could readily model the sedimentation equilibrium data of DR1 in the absence of ZnCl2, using a single species model with a r.m.s. deviation of 0.004 OD and a global {chi}2 of 1.2. An apparent molecular mass of 46.4 kDa was obtained, with molecular mass being the only fitting parameter. This value is in good agreement with the theoretically calculated mass of 44.5 kDa for a HLA-DR1/HA complex, suggesting that the HLA-DR1/HA complex exists as a monomer in the absence of Zn2+. In contrast, global modeling of equilibrium data of DR1 in the presence of 1 mM ZnCl2 resulted in an apparent mass of 79.3 kDa, with an r.m.s. deviation of 0.004 OD and a global {chi}2 of 2.1. This determined mass (79.3 kDa) is lower than the calculated mass (89 kDa) of an HLA-DR1/HA dimer, suggesting that DR1 is in a monomer-dimer equilibrium. The somewhat high {chi}2 value also indicated that a single species model does not represent the experimental data very well. Indeed, when a monomer-dimer model was used in SEDPHATE (40), a much better fit was obtained, with an r.m.s. deviation of 0.003 OD and a global {chi}2 of 1.1. A KD of 0.33 µM for the DR1 monomer-dimer equilibrium was obtained.


Figure 4
View larger version (36K):
[in this window]
[in a new window]

  		FIGURE 4.
Sedimentation equilibrium analysis of Zn2+-induced dimerization of the HLA-DR1/HA complex and the MAM/HLA-DR1/HA complex at rotor speeds of 20,000 ({square} or {blacksquare}), 25,000 rpm ({circ} or •), and 30,000 rpm ({triangleup} or {blacktriangleup}), unless specified. A, representative absorbance distributions for the sedimentation equilibrium of 15 µM MAM with 1 mM Zn2+ ({blacksquare}, •, and {blacktriangleup}) and without Zn2+ ({square}, {circ}, and {Delta}). B, HLA-DR1/HA complex at 5 µM concentration with 1 mM Zn2+ ({blacksquare}, •, and {blacktriangleup}) and without Zn2+ ({square}, {circ}, and {triangleup}), at three rotor speeds of 18,000 ({square} or {blacksquare}), 21,000 rpm ({circ} or •), and 24,000 rpm ({triangleup} or {blacktriangleup}). C, HLA-DR1/HA complex at 2 µM with ZnCl2 at concentrations of 0.1 mM ({square}, {circ}, and {blacktriangleup}) and 0.3 mM ({blacksquare}, •, and {blacktriangleup}), respectively. D, the MAM/HLA-DR1/HA complex with 1 mM ZnCl2 at rotor speeds of 15,000 rpm ({circ}), 20,000 rpm ({blacktriangleup}), 25,000 rpm ({diamondsuit}), and 30,000 rpm ({square}). Distributions were analyzed as part of a global fitting to the absorbance data at multiple loading concentrations. Solid lines are the global best fit distributions.

 
Zinc Titration on the DR1 Dimerization—After determination of the dissociation constant for the DR1 dimerization, it is important to determine the effective Zn2+ concentration for DR1 dimerization. Accordingly, we performed a Zn2+ titration experiment using the AUC sedimentation equilibrium method (Fig. 4C). The HLA-DR1/HA complex at 2 µM concentration was incubated with 0, 0.001, 0.01, 0.1, 0.3, 0.5, 0.7, or 1.0 mM ZnCl2 with HBS buffer and was then subjected to the equilibrium experiment. A representative fitting of the experimental data for DR1 in the presence of ZnCl2, at concentrations of 0.1 and 0.3 mM, is shown in Fig. 4C. Single species modeling of the equilibrium data of DR1 with Zn2+ concentrations between 0 and 0.1 mM resulted in molecular masses ranging from 44.8 to 45.7 kDa (Fig. 4C). These results indicated that the HLA-DR1/HA complex exists as a monomer in the absence of or at low concentrations of Zn2+. At Zn2+ concentrations higher than 0.1 mM, fitting of the sedimentation equilibrium data for DR1 led to molecular masses ranging from 57 to 74 kDa, with the largest mass obtained for DR1 in the presence of 1 mM Zn2+. With 2 µM DR1 and 1 mM Zn2+, the molecular mass value that we determined here is slightly smaller than the one that we determined using 5 µM DR1 in the KD determination experiment (Fig. 4B). The small difference in mass is within experimental error. Alternatively, the mass difference may relate to the effective concentrations of DR1, because the monomer-dimer equilibrium is concentration-dependent. Nevertheless, our experiment demonstrated that the class II MHC HLA-DR1/HA complex can form dimers at Zn2+ concentrations as low as 0.3 mM.

Cooperative Binding of MAM to the HLA-DR1/HA Complex in the Presence of Zn2+—We observed a partially dimerized MAM-(HLA-DR1/HA)2 complex when MAM and DR1 were mixed in a roughly equivalent molar ratio. With MAM in an oversaturated quantity, a completely dimerized MAM2·MHC2 complex was obtained. This implies that cooperative binding occurs between MAM and the HLA-DR1/HA complex in the presence of Zn2+. To verify our hypothesis, we performed a sedimentation equilibrium study for the MAM/HLA-DR1/HA complex in the presence of zinc ion. Under the zinc condition, the sedimentation profile for the MAM-DR1 mixture could not be modeled with a 1:1 interaction between HLA-DR1/HA and MAM. If only 1:1 complex was assumed, global fitting of experimental data using SEDPHATE (39) generated high global reduced {chi}2 (4.0) and high local r.m.s. error (0.042) values. In contrast, if we used a reversible (A + A) + B + B {leftrightharpoons} A + AB + B {leftrightharpoons} (AA)B + B {leftrightharpoons} (AA)BB complex model, with A referring to DR1, (AA) representing DR1 dimer, and B representing MAM, a global analysis of the equilibrium data gave an excellent fit, with a global reduced {chi}2 of 0.8 and local r.m.s. error of 0.004 OD (Fig. 4D). Because of the very weak dimerization of MAM (KD = 1.4 mM) compared with that of DR1 (KD = 0.33 µM), we omitted a MAM dimer from the above model, to reduce the fitting complexity. Nevertheless, inclusion of the MAM dimer in the model equation generated similar results (data not shown).

Under the current model, several dissociation constants could be estimated. For instance, we estimated a KD(AA) of 0.33 µM for DR1 homo-dimerization, from the equilibrium data of the DR1·MAM complex in the presence of Zn2+. This value is identical with the KD value that we determined using DR1 alone, thereby providing a good validation for our modeling method. From this analysis, we estimated a slightly lower binding affinity (KD(AB)) for DR1 binding to MAM in the presence of Zn2+ (0.14 µM) than the KD for the complex in the absence of Zn2+ (0.1 µM). In addition, a KD((AA)B) of 47 nM was estimated for MAM (B) binding to the DR1 dimer (AA). The affinity for MAM binding to a DR1 dimer (47 nM) is about 3-fold higher than that for MAM binding to a DR1 monomer (140 nM). The relatively small magnitude of this difference could imply that DR1 dimerization slightly enhances the binding affinity for the first MAM molecule. In contrast, a KD((AAB)B) of 5.0 µM was estimated for the binding of a second MAM molecule to the MAM·(DR1)2 complex in the presence of Zn2+. This value of 5.0 µM is >100-fold higher than that (47 nM) for the binding of the first MAM molecule to the DR1 dimer. The 100-fold decrease in affinity strongly suggests that cooperative binding of MAM to the HLA-DR1/HA complex occurs upon addition of Zn2+. Thus, in the presence of Zn2+, binding of the first MAM molecule to the DR1 dimer may reduce the binding affinity of the second MAM molecule to the pre-formed MAM·(DR1)2 complex.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
REFERENCES
 
Receptor oligomerization is frequently observed in biological systems, as a mechanism by which the avidity of receptor-ligand interactions can be increased, while at the same time active intracellular signal transduction complexes are formed (47–49). In the immune system, clusters of macromolecules, termed the immunological synapse, have been observed during T cell activation, indicating that multimerization of receptors could be critical for the biological functions of these molecules (50, 51). X-ray crystallographic analyses have indicated that class II MHC can further form a ({alpha}beta)2 superdimer of the MHC heterodimer (2). However, dimerization of soluble class II MHC molecules has not been observed in solution, even under the extreme acidic conditions used for crystallization (1). Although several cell-based studies have suggested that the class II MHC superdimer exists on the surface of living cells (5–7), some of the evidence to support this assertion could attribute to biochemical artifacts (8). In addition, several mutagenesis studies indicated that most of the substitutions made at the MHC superdimer interface did not affect T cell activation (49, 52–55). Although a few of the mutations seemed to modulate T cell activation, it was not clear whether those latter mutations abolish the actual formation of the MHC superdimer or whether they induce other effects, such as reduction of cell surface expression of class II MHC and/or abrogation of binding of accessory molecules (49).

In this study, we have investigated the molecular interaction between MAM and class II MHC. Our results indicated that Zn2+ neither participates directly in the binding between MAM and class II MHC molecules nor induces the dimerization of MAM in solution. Velocity sedimentation experiments revealed that formation of the complex between MAM and HLA-DR1/HA does not require the Zn2+ ion; after addition of chelator (EDTA), the same peak, representing the complex, was seen. Consistently, no Zn2+ ion was detected in the crystal structures of the MAM/HLA-DR1/HA complexes under various conditions, with EDTA, Cd2+, or Zn2+ (this study and see Refs. 27 and 32). Binding studies using the AUC and SPR techniques further confirmed that the Zn2+ ion is not directly involved in the binding between MAM and the HLA-DR1/HA complex, given that MAM binds the HLA-DR1/HA complex with high affinity in the absence of the Zn2+ ion.

Although Zn2+ does not directly participate in the interaction between MAM and class II MHC, we unexpectedly found that the Zn2+ ion triggers dimerization of the HLA-DR1/HA complex. In the presence of Zn2+, the HLA-DR1/HA complex forms a dimer of the heterodimer, with a dissociation constant of 0.33 µM. The dimerized HLA-DR1 binds the first MAM molecule with a slightly higher affinity (3-fold) than does the monomer HLA-DR1. Furthermore, our results showed that binding of the first MAM molecule to the dimerized MHC complex greatly reduced the binding affinity of the DR1 dimer for the second MAM molecule. Our data strongly suggest that the addition of Zn2+ induces cooperative binding of MAM to the HLA-DR1/HA complex. Evidently, Zn2+ triggers the dimerization of the MAM/HLA-DR1/HA complex via a Zn2+-mediated HLA-DR1/HA dimer. It is currently not clear whether the HLA-DR superdimer described by Brown et al. (1) represents the structure of the Zn2+-induced DR1 dimer, because no Zn2+ was found in those structures. Structure determination of the DR1 molecule in the presence of Zn2+, and structure-based mutagenesis studies, will be required to investigate whether the Zn2+-induced dimerization of HLA-DR1 plays any roles in the biological function of the class II MHC molecule. Nonetheless, several studies, including ours, clearly demonstrated that dimerization or even oligomerization of MHC class II molecules at the cell surface is absolutely required for inflammatory cytokine gene expression in human monocytes. What makes our observation unique is the ability of the HLA-DR dimer to bind two different MAM molecules. Such recognition of MAM-bound HLA-DR by T cells will significantly increase the ability of these complexes to trigger TCR microclustering at the immunological synapse where signaling is initiated and sustained leading to optimal T cell activation (56).

Previously, we failed to find Zn2+ in the crystal structure of the MAM/HLA-DR1/HA complex when the crystals were grown in the presence of 1 mM Zn2+ (27), although our new studies have shown that the HLA-DR1/HA complex forms homodimer in the presence of Zn2+. It is not uncommon that Zn2+ ion was not detected in the solved structures for protein crystals grown in or soaked with Zn2+. We searched the protein data base and found that more than 20 structures involving HLA-DR molecules have been determined. Only four of these crystals, namely the SEAD227A-DR1 complex (Protein Data Bank 1LO5 (57)), the SpeC-DR2a complex (Protein Data Bank 1LO5 1HQR (58)), the SEH-DR1 complex (Protein Data Bank 1HXY (59)), and the MAM·DR1 complex (Protein Data Bank 1R5I (27)), were grown or soaked in various concentrations of Zn2+. SpeC and SEH are known to require Zn2+ for binding to class II MHC. Indeed, one Zn2+ ion was found at the interface between the SAg and the DR molecule in each of the complexes. In contrast, although the crystal of the SEAD227A/HLA-DR1/HA complex was grown in the presence of 1 mM ZnCl2, no zinc was found in that crystal structure (57).

We have demonstrated that a dimer of the MAM/HLA-DR1/HA complex can form via a Zn2+-induced HLA-DR1 dimer. It is intriguing that the MAM·DR1 complex forms a dimerized complex through a MAM homodimer in the crystal structures (27). In fact, all other three complexes mentioned above (SpeC-DR2a, SEH-DR1, and SEAD227A-DR1 complexes) are monomeric in the crystal structures, even though Zn2+ was included in the crystallization buffer (57–59). The absence of a Zn2+-coordinated HLA-DR dimer in the crystal structures could indicate that interactions of class II MHC with the SAg suppress the Zn2+-induced dimerization of the HLA-DR molecule. Alternatively, crystal-packing forces could play a role in elimination of the DR1 dimer in the crystal.

Nevertheless, our results clearly indicate that a dimer of the class II MHC heterodimer is formed in the presence of zinc. In fact, zinc is known to be essential for the highly proliferating cells in the immune system (60). Notably, it has been reported that zinc can induce polyclonal activation of human B lymphocytes from blood, spleen, and lymph nodes in vitro (61). In serum, zinc occurs at concentrations in the range of 10–120 µM (62–65). A much higher concentration of Zn2+ (0.3 mM) was required in this study to allow detection of the effect of Zn2+ on the oligomeric state of HLA-DR1. The possible functional significance of dimers of class II MHC heterodimers has been extensively discussed (1, 2, 5, 6, 49, 53, 54, 66). In addition, it was recently reported that zinc homeostasis plays significant roles in the maturation of dendritic cells and regulation of surface expression of MHC class II (67). Addition of a zinc chelator was found to increase the surface expression of MHC class II on dendritic cells, leading to enhanced CD4+ T cell activation (67). Although speculative at this point, zinc-induced dimerization of class II MHC could be involved in the regulation of surface expression of MHC II. By analogy to the zinc-induced dimerization of the inhibitory receptors of human natural killer cells that is critical for their inhibitory function (68), it is possible that Zn2+-induced dimerization of MHC II could provide inhibitory signals for resting APCs. Thus, our results suggest that Zn2+-induced class II MHC dimerization is important for the biological function of the MHC molecules.

Our results are also consistent with the immunological finding that metal ions, Zn2+ in particular, play an important role in the biological function of certain SAgs (9, 15, 19, 29, 30, 58). Zinc may regulate the SAg activity in several ways (41). In addition to its direct participation in the interactions between SAgs and their host receptors (9, 58, 59), zinc, as our results have indicated, induces dimerization of host receptors such as class II MHC molecules, thereby modulating the activity of SAgs.


   FOOTNOTES
 
* This work was supported by Grants AI50628 and AI64637 from the National Institutes of Health (to H. L.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

The atomic coordinates and structure factors (code 2OJE) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/). Back

2 Present address: ImmunoGen Inc., 128 Sidney St., Cambridge, MA 02139. Back

1 To whom correspondence should be addressed: Wadsworth Center, New York State Department of Health, 120 New Scotland Ave., Albany, NY 12208. Tel.: 518-486-9154; Fax: 518-474-7992; E-mail: lih{at}wadsworth.org.

3 The abbreviations used are: MHC, major histocompatibility complex; MAM, mycoplasma arthritidis-derived mitogen; SPR, surface plasmon resonance; HA, hemagglutinin peptide-(306–318); TCR, T cell receptor; APC, antigenpresenting cell; SAg, superantigen; SEA, staphylococcal enterotoxin A; AUC, analytical ultracentrifugation; SV, sedimentation velocity; HBS, Hepes-buffered saline; RU, resonance unit; r.m.s., root-mean-square. Back


   ACKNOWLEDGMENTS
 
We thank A. Verschoor for a critical reading of the manuscript, L. J. Stern for the gift of HLA-DR1 expression plasmids, and the core facilities at the Wadsworth Center, including the Peptide Synthesis Core Facility for the synthesis of the HA peptide, the Molecular Genetics Core for DNA sequencing, the Biochemistry Core for assistance in analytical ultracentrifuge experiments, the Immunology Core for affinity measurement, and the Macromolecular Crystallography Core for use of the facility. We thank R. Sweet and M. Becker at National Synchrotron Light Source for assistance in x-ray data collection. The x-ray diffraction facility at the National Synchrotron Light Source is supported by the Department of Energy and by grants from the National Institutes of Health.



   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Brown, J. H., Jardetzky, T. S., Gorga, J. C., Stern, L. J., Urban, R. G., Strominger, J. L., and Wiley, D. C. (1993) Nature 364, 33–39[CrossRef][Medline] [Order article via Infotrieve]
  2. Schafer, P. H., Pierce, S. K., and Jardetzky, T. S. (1995) Semin. Immunol. 7, 389–398[CrossRef][Medline] [Order article via Infotrieve]
  3. Chen, Z. Z., McGuire, J. C., Leach, K. L., and Cambier, J. C. (1987) J. Immunol. 138, 2345–2352[Abstract]
  4. Cambier, J. C., Morrison, D. C., Chien, M. M., and Lehmann, K. R. (1991) J. Immunol. 146, 2075–2082[Abstract]
  5. Schafer, P. H., and Pierce, S. K. (1994) Immunity 1, 699–707[CrossRef][Medline] [Order article via Infotrieve]
  6. Roucard, C., Garban, F., Mooney, N. A., Charron, D. J., and Ericson, M. L. (1996) J. Biol. Chem. 271, 13993–14000[Abstract/Free Full Text]
  7. Cherry, R. J., Wilson, K. M., Triantafilou, K., O'Toole, P., Morrison, I. E., Smith, P. R., and Fernandez, N. (1998) J. Cell Biol. 140, 71–79[Abstract/Free Full Text]
  8. Hitzel, C., Gruneberg, U., van Ham, M., Trowsdale, J., and Koch, N. (1999) J. Immunol. 162, 4671–4676[Abstract/Free Full Text]
  9. Li, H., Llera, A., Malchiodi, E. L., and Mariuzza, R. A. (1999) Annu. Rev. Immunol. 17, 435–466[CrossRef][Medline] [Order article via Infotrieve]
  10. Kotzin, B. L., Leung, D. Y., Kappler, J., and Marrack, P. (1993) Adv. Immunol. 54, 99–166[Medline] [Order article via Infotrieve]
  11. Abe, J., Kotzin, B. L., Jujo, K., Melish, M. E., Glode, M. P., Kohsaka, T., and Leung, D. Y. (1992) Proc. Natl. Acad. Sci. U. S. A. 89, 4066–4070[Abstract/Free Full Text]
  12. Conrad, B., Weidmann, E., Trucco, G., Rudert, W. A., Behboo, R., Ricordi, C., Rodriquez-Rilo, H., Finegold, D., and Trucco, M. (1994) Nature 371, 351–355[CrossRef][Medline] [Order article via Infotrieve]
  13. Renno, T., and Acha-Orbea, H. (1996) Immunol. Rev. 154, 175–191[CrossRef][Medline] [Order article via Infotrieve]
  14. McCormick, J. K., Yarwood, J. M., and Schlievert, P. M. (2001) Annu. Rev. Microbiol. 55, 77–104[CrossRef][Medline] [Order article via Infotrieve]
  15. Hudson, K. R., Tiedemann, R. E., Urban, R. G., Lowe, S. C., Strominger, J. L., and Fraser, J. D. (1995) J. Exp. Med. 182, 711–720[Abstract/Free Full Text]
  16. Hurley, J. M., Shimonkevitz, R., Hanagan, A., Enney, K., Boen, E., Malmstrom, S., Kotzin, B. L., and Matsumura, M. (1995) J. Exp. Med. 181, 2229–2235[Abstract/Free Full Text]
  17. Jardetzky, T. S., Brown, J. H., Gorga, J. C., Stern, L. J., Urban, R. G., Chi, Y. I., Stauffacher, C., Strominger, J. L., and Wiley, D. C. (1994) Nature 368, 711–718[CrossRef][Medline] [Order article via Infotrieve]
  18. Kim, J., Urban, R. G., Strominger, J. L., and Wiley, D. C. (1994) Science 266, 1870–1874[Abstract/Free Full Text]
  19. Kozono, H., Parker, D., White, J., Marrack, P., and Kappler, J. (1995) Immunity 3, 187–196[CrossRef][Medline] [Order article via Infotrieve]
  20. Li, P. L., Tiedemann, R. E., Moffat, S. L., and Fraser, J. D. (1997) J. Exp. Med. 186, 375–383[Abstract/Free Full Text]
  21. Papageorgiou, A. C., Acharya, K. R., Shapiro, R., Passalacqua, E. F., Brehm, R. D., and Tranter, H. S. (1995) Structure (Camb.) 3, 769–779
  22. Baker, H. M., Proft, T., Webb, P. D., Arcus, V. L., Fraser, J. D., and Baker, E. N. (2004) J. Biol. Chem. 279, 38571–38576[Abstract/Free Full Text]
  23. Baker, M., Gutman, D. M., Papageorgiou, A. C., Collins, C. M., and Acharya, K. R. (2001) Protein Sci. 10, 1268–1273[CrossRef][Medline] [Order article via Infotrieve]
  24. Sundstrom, M., Abrahmsen, L., Antonsson, P., Mehindate, K., Mourad, W., and Dohlsten, M. (1996) EMBO J. 15, 6832–6840[Medline] [Order article via Infotrieve]
  25. Cole, B. C. (1991) Curr. Top. Microbiol. Immunol. 174, 107–119[Medline] [Order article via Infotrieve]
  26. Cole, B. C., and Atkin, C. L. (1991) Immunol. Today 12, 271–276[CrossRef][Medline] [Order article via Infotrieve]
  27. Zhao, Y., Li, Z., Drozd, S., Guo, Y., Mourad, W., and Li, H. (2004) Structure (Camb.) 12, 277–288
  28. Bernatchez, C., Al-Daccak, R., Mayer, P. E., Mehindate, K., Rink, L., Mecheri, S., and Mourad, W. (1997) Infect. Immun. 65, 2000–2005[Abstract]
  29. Etongue-Mayer, P., Langlois, M. A., Ouellette, M., Li, H., Younes, S., Al-Daccak, R., and Mourad, W. (2002) Eur. J. Immunol. 32, 50–58[CrossRef][Medline] [Order article via Infotrieve]
  30. Langlois, M. A., El Fakhry, Y., and Mourad, W. (2003) J. Biol. Chem. 278, 22309–22315[Abstract/Free Full Text]
  31. Langlois, M. A., Etongue-Mayer, P., Ouellette, M., and Mourad, W. (2000) Eur. J. Immunol. 30, 1748–1756[CrossRef][Medline] [Order article via Infotrieve]
  32. Zhao, Y., Li, Z., Drozd, S., Guo, Y., Stack, R., Hauer, C., and Li, H. (2004) Acta Crystallogr. Sect. D Biol. Crystallogr. 60, 353–356[CrossRef][Medline] [Order article via Infotrieve]
  33. Frayser, M., Sato, A. K., Xu, L., and Stern, L. J. (1999) Protein Expression Purif. 15, 105–114[CrossRef][Medline] [Order article via Infotrieve]
  34. Beckett, D., Kovaleva, E., and Schatz, P. J. (1999) Protein Sci. 8, 921–929[Medline] [Order article via Infotrieve]
  35. Crawford, F., Kozono, H., White, J., Marrack, P., and Kappler, J. (1998) Immunity 8, 675–682[CrossRef][Medline] [Order article via Infotrieve]
  36. Kadima, W. (1999) Biochemistry 38, 13443–13452[CrossRef][Medline] [Order article via Infotrieve]
  37. Hill, C. P., Dauter, Z., Dodson, E. J., Dodson, G. G., and Dunn, M. F. (1991) Biochemistry 30, 917–924[CrossRef][Medline] [Order article via Infotrieve]
  38. Brunger, A. T., Adams, P. D., Clore, G. M., DeLano, W. L., Gros, P., Grosse-Kunstleve, R. W., Jiang, J. S., Kuszewski, J., Nilges, M., Pannu, N. S., Read, R. J., Rice, L. M., Simonson, T., and Warren, G. L. (1998) Acta Crystallogr. Sect. D Biol. Crystallogr. 54, 905–921[CrossRef][Medline] [Order article via Infotrieve]
  39. Vistica, J., Dam, J., Balbo, A., Yikilmaz, E., Mariuzza, R. A., Rouault, T. A., and Schuck, P. (2004) Anal. Biochem. 326, 234–256[CrossRef][Medline] [Order article via Infotrieve]
  40. Schuck, P., Perugini, M. A., Gonzales, N. R., Howlett, G. J., and Schubert, D. (2002) Biophys. J. 82, 1096–1111
  41. Li, H., Zhao, Y., Guo, Y., Vanvranken, S. J., Li, Z., Eisele, L., and Mourad, W. (2007) Mol. Immunol. 44, 763–773[CrossRef][Medline] [Order article via Infotrieve]
  42. Wu, L. C., Tuot, D. S., Lyons, D. S., Garcia, K. C., and Davis, M. M. (2002) Nature 418, 552–556[CrossRef][Medline] [Order article via Infotrieve]
  43. Fremont, D. H., Hendrickson, W. A., Marrack, P., and Kappler, J. (1996) Science 272, 1001–1004[Abstract]
  44. Yang, J., Swaminathan, C. P., Huang, Y., Guan, R., Cho, S., Kieke, M. C., Kranz, D. M., Mariuzza, R. A., and Sundberg, E. J. (2003) J. Biol. Chem. 278, 50412–50421[Abstract/Free Full Text]
  45. van der Merwe, P. A., Barclay, A. N., Mason, D. W., Davies, E. A., Morgan, B. P., Tone, M., Krishnam, A. K., Ianelli, C., and Davis, S. J. (1994) Biochemistry 33, 10149–10160[CrossRef][Medline] [Order article via Infotrieve]
  46. Malchiodi, E. L., Eisenstein, E., Fields, B. A., Ohlendorf, D. H., Schlievert, P. M., Karjalainen, K., and Mariuzza, R. A. (1995) J. Exp. Med. 182, 1833–1845[Abstract/Free Full Text]
  47. Heldin, C. H. (1995) Cell 80, 213–223[CrossRef][Medline] [Order article via Infotrieve]
  48. Ullrich, A., and Schlessinger, J. (1990) Cell 61, 203–212[CrossRef][Medline] [Order article via Infotrieve]
  49. Hayball, J. D., and Lake, R. A. (2005) Mol. Cell. Biochem. 273, 1–9[CrossRef][Medline] [Order article via Infotrieve]
  50. Monks, C. R., Freiberg, B. A., Kupfer, H., Sciaky, N., and Kupfer, A. (1998) Nature 395, 82–86[CrossRef][Medline] [Order article via Infotrieve]
  51. Grakoui, A., Bromley, S. K., Sumen, C., Davis, M. M., Shaw, A. S., Allen, P. M., and Dustin, M. L. (1999) Science 285, 221–227[Abstract/Free Full Text]
  52. Yadati, S., Nydam, T., Demian, D., Wade, T. K., Gabriel, J. L., Barisas, B. G., and Wade, W. F. (1999) Immunol. Lett. 67, 47–55[CrossRef][Medline] [Order article via Infotrieve]
  53. Nydam, T., Wade, T. K., Yadati, S., Gabriel, J. L., Barisas, B. G., and Wade, W. F. (1998) Int. Immunol. 10, 1237–1249[Abstract/Free Full Text]
  54. Lindstedt, R., Monk, N., Lombardi, G., and Lechler, R. (2001) J. Immunol. 166, 800–808[Abstract/Free Full Text]
  55. Goodman, S., Sawada, T., Barbosa, J. A., Cole, B., Pergolizzi, R., Silver, J., Mellins, E., and Chang, M. D. (1995) J. Immunol. 155, 1210–1217[Abstract]
  56. Saito, T., and Yokosuka, T. (2006) Curr. Opin. Immunol. 18, 305–313[CrossRef][Medline] [Order article via Infotrieve]
  57. Petersson, K., Thunnissen, M., Forsberg, G., and Walse, B. (2002) Structure (Lond.) 10, 1619–1626[Medline] [Order article via Infotrieve]
  58. Li, Y., Li, H., Dimasi, N., McCormick, J. K., Martin, R., Schuck, P., Schlievert, P. M., and Mariuzza, R. A. (2001) Immunity 14, 93–104[CrossRef][Medline] [Order article via Infotrieve]
  59. Petersson, K., Hakansson, M., Nilsson, H., Forsberg, G., Svensson, L. A., Liljas, A., and Walse, B. (2001) EMBO J. 20, 3306–3312[CrossRef][Medline] [Order article via Infotrieve]
  60. Ibs, K. H., and Rink, L. (2003) J. Nutr. 133, S1452–S1456[Abstract/Free Full Text]
  61. Cunningham-Rundles, S., Cunningham-Rundles, C., Dupont, B., and Good, R. A. (1980) Clin. Immunol. Immunopathol. 16, 115–122[CrossRef][Medline] [Order article via Infotrieve]
  62. Cunningham, B. C., Bass, S., Fuh, G., and Wells, J. A. (1990) Science 250, 1709–1712[Abstract/Free Full Text]
  63. Thorlacius-Ussing, O. (1987) Neuroendocrinology 45, 233–242[CrossRef][Medline] [Order article via Infotrieve]
  64. Harrison, R. T. (1987) Harrison's Principles of Internal Medicine (Braunwald, E., Hauser, S. L., Fauci, A. S., Longo, D. L., Kasper, D. L., and Jameson, J. L., Eds.), Vol. 1, pp. 455–461, The McGraw-Hill Companies, Inc., New York
  65. Lentner, C. (1981) Geigy Scientific Tables (Lentner, C., ed) Vol. 3, pp. 78–89, Ciba-Geigy Ltd., Basle, Ardsley, NY
  66. Ploegh, H., and Benaroch, P. (1993) Nature 364, 16–17[Medline] [Order article via Infotrieve]
  67. Kitamura, H., Morikawa, H., Kamon, H., Iguchi, M., Hojyo, S., Fukada, T., Yamashita, S., Kaisho, T., Akira, S., Murakami, M., and Hirano, T. (2006) Nat. Immun. 7, 971–977[CrossRef]
  68. Fan, Q. R., Long, E. O., and Wiley, D. C. (2000) J. Biol. Chem. 275, 23700–23706[Abstract/Free Full Text]

Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?



This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
282/9/5991    most recent
M608482200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, H.
Right arrow Articles by Mourad, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, H.
Right arrow Articles by Mourad, W.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2007 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement